Skip to main content

Chanakya

Encube Ethicals IPO: Rs. 3,000 Crore OFS

Encube Ethicals IPO: Rs. 3,000 Crore OFS, Financials and Business Overview

IPO Overview

Encube Ethicals Limited received SEBI observations for its proposed IPO on 4 November 2026. The proposed Rs. 3,000 crore bookbuilding issue consists entirely of an offer for sale, with no fresh capital raised by the company.

The shares are proposed for listing on BSE and NSE. IPO dates, price band, lot size and listing date remain unannounced. SEBI observations permit the offering process to proceed; they are not an investment recommendation.

Particulars Details
Proposed Issue Size Rs. 3,000 crore
Issue Structure Entirely Offer for Sale
Face Value Rs. 1 per share
IPO Dates To be announced
Price Band and Lot Size To be announced
Listing Exchanges BSE and NSE
Pre-issue Shares 30,38,84,790
Post-issue Shares 30,38,84,790, subject to other capital changes
DRHP Filing 3 August 2026
SEBI Observations 4 November 2026

Investor Reservation

Investor Category Proposed Allocation
Qualified Institutional Buyers Not more than 50% of the offer
Retail Investors Not less than 35%
Non-Institutional Investors Not less than 15%

Retail applications are limited to Rs. 2 lakh. Small NII applications exceed Rs. 2 lakh and extend up to Rs. 10 lakh, while large NII applications exceed Rs. 10 lakh. Any employee reservation and eligibility should be confirmed from final offer documents.

Business and Operating Presence

Incorporated in September 1995, Encube Ethicals is a pharmaceutical formulations company specialising in topical and transdermal dosage forms. It serves 50 countries, including the United States, the UK, European markets and India.

The company operates through three business verticals:

  • Global Generics: Development and commercialisation of generic pharmaceutical formulations.
  • Global CDMO: Contract development and manufacturing services for pharmaceutical customers.
  • India Branded Formulations: Marketing branded products through its domestic distribution network.

Its capabilities span research, formulation development, manufacturing, regulatory compliance and commercialisation. Manufacturing facilities and R&D infrastructure support its product pipeline and relationships with international pharmaceutical companies.

As of 31 March 2026, Encube reported 1,695 permanent employees and 982 factory workers.

Key Business Strengths

  • Specialisation in topical and transdermal formulations.
  • Presence across regulated international markets.
  • Integrated generics, CDMO and branded-formulations businesses.
  • R&D capabilities supporting product development.
  • Established manufacturing infrastructure and customer relationships.

Regulatory compliance, successful product launches and consistent manufacturing quality remain essential to sustaining these strengths.

Financial Performance

Restated consolidated figures, Rs. crore

Particulars FY2026 FY2025 FY2024
Total Income 1,911.80 1,369.00 1,098.20
EBITDA 663.30 452.10 297.60
Profit After Tax 436.70 249.60 156.10
Total Assets 2,792.10 2,300.10 1,871.80
Net Worth 1,953.60 1,512.80 1,258.40
Reserves and Surplus 1,915.20 1,495.20 1,243.40
Borrowings 221.70 230.50 228.10

FY2026 total income increased 39.65%, EBITDA rose 46.72%, and PAT increased 74.96%. Profit growth exceeded income growth, indicating improved overall profitability.

EBITDA as a proportion of total income increased from approximately 33.02% to 34.70%, while PAT margin on total income improved from 18.23% to 22.84%.

Borrowings declined 3.82% to Rs. 221.70 crore, while net worth increased 29.14% to Rs. 1,953.60 crore.

Chanakya Interpretation: Strong earnings growth and relatively modest borrowings support the business profile. Investors should examine product-wise profitability, cash conversion and whether recent margins are sustainable.

Key Performance Indicators and Valuation

Indicator Reported FY2026 Reading
ROE 25.65%
ROCE 32.30%
Debt/Equity 0.13 times
Return on Net Worth 25.21%
PAT Margin 23.62%
EBITDA Margin 35.88%
NAV per Share Rs. 64.29
EPS Rs. 14.37

The reported margin KPIs differ from calculations using total income, reflecting a different denominator or definition. Investors should refer to the offer document’s calculation methodology.

P/E and price-to-book valuation await the price band. As the offer is entirely an OFS, it does not itself increase the share count or dilute EPS.

IPO Proceeds and Selling Shareholders

Encube Ethicals will receive no IPO proceeds. The money raised will go to the selling shareholders, after applicable selling expenses.

Selling Shareholder Category Proposed OFS Amount
Mehul Madhusudan Shah Promoter Up to Rs. 2,000 crore
Frontier Investment Holdings Pte. Limited Corporate shareholder Up to Rs. 1,000 crore
Total Rs. 3,000 crore

The final number of shares sold will depend on pricing and offer terms.

Mehul Madhusudan Shah is the company’s promoter. The promoter and promoter group hold 80.63% before the IPO, while public shareholders hold 19.37%. Post-offer ownership will depend on the final stake sale.

Chanakya’s Assessment Points

Encube’s financial performance shows strong growth, improving profitability and manageable borrowings. However, the investment decision should await pricing and a detailed examination of:

  • Regulatory inspections, observations and remediation requirements.
  • US generic-drug pricing and competitive intensity.
  • Product, customer and geographical concentration.
  • R&D productivity and commercialisation of new products.
  • Operating cash flow, working capital and capital expenditure.
  • Sustainability of margins and returns on capital.

Chanakya View: Await Pricing. Business growth merits attention, but valuation will determine whether the proposed offer provides an attractive investment opportunity.

Company Address and Contact

Registered office: 803, B Wing, HDIL Kaledonia, Sahar Road, Andheri East, Mumbai, Maharashtra – 400069.

Management interaction route: Company Secretary / Compliance Office
Telephone: +91 22 62288000
Email: compliance.cs@encubeethicals.com
Website: www.encubeethicals.com

Bookrunning lead managers: JM Financial Limited, Axis Capital Limited and Kotak Mahindra Capital Company Limited.

Registrar: MUFG Intime India Private Limited
Telephone: 022-49186000
IPO email: encubeethicals.ipo@in.mpms.mufg.com

Frequently Asked Questions

What is the Encube Ethicals IPO?
It is a proposed Rs. 3,000 crore mainboard IPO consisting entirely of an offer for sale.

When will the IPO open?
The opening and closing dates have not been announced.

What are the price band and lot size?
Both remain unannounced.

Will Encube receive funds from the IPO?
No. Proceeds will go to the selling shareholders.

Where will the shares be listed?
The shares are proposed for listing on BSE and NSE.

AEO / GEO Answer Summary

Encube Ethicals proposes a Rs. 3,000 crore, entirely OFS IPO. The pharmaceutical company specialises in topical and transdermal formulations across generics, CDMO and Indian branded products. FY2026 total income reached Rs. 1,911.80 crore, with PAT of Rs. 436.70 crore. IPO dates, price band and lot size remain awaited. Valuation, regulatory compliance and earnings sustainability are key assessment factors.

Leave a Reply

Your email address will not be published. Required fields are marked *